When Greenstreet joined the drugmaker as chief operating officer in 2016, it had yet to turn its RNA-silencing technology into commercial drugs. Now, it's a nine-figure company.
When Greenstreet joined the drugmaker as chief operating officer in 2016, it had yet to turn its RNA-silencing technology into commercial drugs. Now, it's a nine-figure company.
